Trials / Conditions / Autosomal Dominant Polycystic Kidney

Autosomal Dominant Polycystic Kidney

24 registered clinical trials studyying Autosomal Dominant Polycystic Kidney — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Glucagon-Like Peptide-1 Receptor Agonist in ADPKD NCT06582875	University of Colorado, Denver	Phase 2
Active Not Recruiting	Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) NCT06391450	Hannover Medical School	Phase 4
Recruiting	Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases NCT05996731	Mario Negri Institute for Pharmacological Research	N/A
Active Not Recruiting	Outcome of ADPKD With Octreotide LAR NCT06193616	Mario Negri Institute for Pharmacological Research	—
Completed	Thyroid Hormones in ADPKD NCT05646420	Mario Negri Institute for Pharmacological Research	N/A
Active Not Recruiting	Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD NCT06496542	University of Colorado, Denver	N/A
Unknown	Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepat NCT05500157	Radboud University Medical Center	N/A
Recruiting	A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease NCT05478083	University Medical Center Groningen	Phase 2
Completed	Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease NCT05401409	Western Sydney Local Health District	N/A
Completed	Treatment of Vascular Stiffness in ADPKD NCT05228574	Erasmus Medical Center	Phase 4
Active Not Recruiting	Daily Caloric Restriction in ADPKD NCT04907799	University of Colorado, Denver	N/A
Terminated	Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease NCT04064346	Palladio Biosciences	Phase 3
Completed	To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunte NCT04908462	AceLink Therapeutics, Inc.	Phase 1
Recruiting	Analysis of Patients With Autosomal Dominant Polycystic Kidney NCT06759142	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Unknown	Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt NCT04310319	Esther Meijer	N/A
Completed	Dietary Intervention in ADPKD on Tolvaptan NCT03858439	McMaster University	N/A
Terminated	A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON NCT03918447	Biogen	Phase 3
Terminated	An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) NCT03749447	Biogen	Phase 3
Unknown	Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidne NCT03596957	Lisbet Brandi	Phase 4
Completed	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases NCT03366337	Biogen	Phase 2
Recruiting	A Prospective Observational Study of Foam Sclerotherapy . NCT04111692	Mayo Clinic	—
Completed	Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD NCT03203642	Kadmon, a Sanofi Company	Phase 2
Active Not Recruiting	Statin Therapy in Patients With Early Stage ADPKD NCT03273413	University of Colorado, Denver	Phase 4
Completed	A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease NCT03102632	The Rogosin Institute	N/A